Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

Precigen Q1 Earnings Call Highlights

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.

On the company’s earnings call, President and CEO Dr. Helen Sabzevari said PAPZIMEOS generated net product revenue of $21.6 million in the first quarter, its first full quarter of availability, compared with $3.4 million in the fourth quarter of 2025. Total company revenue for the quarter was $23.3 million.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.